[{"orgOrder":0,"company":"MediWound","sponsor":"Balance Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues NexoBrid\u2019s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Genfa Medica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements with Genfa Medica","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues Global Expansion with Distribution Agreement for in United Arab Emirates with Ghassan Aboud Group","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain enriched proteolytic enzymes","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Soroka Medical Cente","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"MWPC005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Soroka Medical Cente","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Soroka Medical Cente"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic enzymes enriched in bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Initiation of U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched In Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$211.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.20999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Topical","sponsorNew":"MediWound \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Initial Data from its U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound's EscharEx\u00ae Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Expands Global Presence as NexoBrid\u00ae Gains Approval in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results in U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Expands NexoBrid\u2019s Global Presence with Marketing Approval in Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Approval of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces an Additional $10 Million Award from BARDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.17999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results in Its U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Commercial Launch of NexoBrid in Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with M\u00f6lnlycke on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces U.S. Commercial Availability of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid\u00ae Development for the U.S. Army","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ U.S. Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Deploys NexoBrid\u00ae for Emergency Supply","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"3M Health Care","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with 3M on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid\u00ae Distribution in Europe","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid\u00ae to Treat Pediatric Patients","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Topline Results from its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"MiMedx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with MIMEDX on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces $25 Million Strategic Private Placement Financing","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"13","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Secures $1625M from European Innovation Council Program","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"MediWound","amount2":0.02,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ EIC","highestDevelopmentStatusID":"13","companyTruncated":"MediWound \/ EIC"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Reports Positive Results from U.S. NexoBrid\u00ae Expanded Access Protocol","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives FDA Approval for NexoBrid\u00ae in Pediatric Patients with Severe Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"MediWound \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by MediWound
Details :
NexoBrid (anacaulase-bcdb) is a topical biological product that enzymatically removes nonviable burn tissue, approved for treating patients with deep partial- and/or full-thickness thermal burns.
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, approved the treatment of severe burns.
Details :
The funding will significantly advance the Company’s EscharEx (bromelain enriched proteolytic enzyme) development program for patients with diabetic foot ulcers.
Brand Name : EscharEx
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) :
Bromelain Enriched Proteolytic Enzyme
Details :
The net proceeds to advance EscharEx (bromelain enriched proteolytic enzyme) pre-commercial activities & expedite the development for the treatment of patients with diabetic foot ulcers.
Brand Name : EscharEx
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2024
Lead Product(s) :
Bromelain Enriched Proteolytic Enzyme
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, which is under phase 3 clinical development for the treatment of eschar, in patients with deep partial- and/or full-thickness ther...
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Details :
The collaboration aims for the promotion of NexoBrid (anacaulase-bcdb), a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in Germany, Austria, Belgium, the Netherlands and Luxemburg.
Details :
EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds...
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Details :
The funding will be used to develop NexoBrid (anacaulase-bcdb), a topically administered biological product that enzymatically removes nonviable burn tissue, as a non-surgical solution for field-care burn treatment for the U.S. Army.
Market Place
Reset All
